Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative anti-HBV strategy comparison in HBV-associated liver cancer
ChiCTR-TRC-11001683Phase 2Completed
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lamivudine, foscarnet sodium, adefovir dipivoxil and entecavir in hepatocellular carcinoma (HCC) and hepatitis B (HBV) (4 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Quantification of hepatitis B markers and HBV DNA, Immune function and 5 more. Started Sep 2011; status: completed.
02
Drugs
lamivudinefoscarnet sodiumadefovir dipivoxilentecavir
03
Conditions
hepatocellular carcinoma (HCC)hepatitis B (HBV)
Beyond the preview
Go deeper on ChiCTR-TRC-11001683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-11001683.